Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
128 studies found for:    TP53
Show Display Options
Rank Status Study
1 Recruiting Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt
Condition: Advanced Solid and Hematological TP53wt Tumors
Interventions: Drug: HDM201;   Drug: ancillary treatment
2 Recruiting Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Ibrutinib
3 Active, not recruiting Magnetic Resonance Imaging Screening in Li Fraumeni Syndrome
Condition: Li-Fraumeni Syndrome
Interventions: Other: Whole body MRI;   Other: Psychological questionnaires
4 Active, not recruiting Biomarker Monitoring in TP53 Mutation Carriers
Conditions: Li-Fraumeni Syndrome;   Hereditary Cancer Syndromes;   TP53 Gene Germline Mutation Carrier
Intervention:
5 Active, not recruiting A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome
Condition: Li-Fraumeni Syndrome
Intervention: Drug: Metformin
6 Not yet recruiting p53 Gene Therapy in Treatment of Diabetes Concurrent With Hepatocellular Carcinoma
Conditions: HCC;   Diabetes
Interventions: Drug: p53 gene therapy;   Drug: Trans-catheter embolization
7 Terminated Study of SNX-5422 in TP53 Null Cancers
Condition: Cancer
Intervention: Drug: SNX-5422
8 Recruiting A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Have Received a Prior B-cell Receptor Inhibitor.
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Venetoclax
9 Recruiting A Study Evaluating Venetoclax in Subjects With Chronic Lymphocytic Leukemia Whose Cancer Has Come Back or Who Had No Response to Previous Cancer Treatments Including Subjects Missing Part of Their Chromosome 17, or TP53 Gene Mutation; or Who Received Prior Treatment With a B-Cell Receptor Inhibitor
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: Venetoclax
10 Recruiting Clinical and Genetic Studies of Li-Fraumeni Syndrome
Conditions: Li-Fraumeni Syndrome;   Neoplasms;   Tp53 Mutations
Intervention:
11 Recruiting The p53 Breast Cancer Trial
Conditions: Locally Advanced Breast Cancer;   Metastatic Breast Carcinoma
Intervention: Drug: Cyclophosphamide
12 Not yet recruiting Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation
Condition: Small Cell Lung Cancer
Intervention: Drug: AZD1775
13 Unknown  Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Surgery combined with rAd-p53 gene therapy;   Procedure: Surgery
14 Recruiting Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome
Condition: Li-Fraumeni Syndrome
Intervention:
15 Recruiting Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Rituximab;   Drug: Bendamustine;   Drug: Venetoclax;   Biological: Obinutuzumab;   Drug: Ibrutinib
16 Recruiting Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma
Condition: Advanced Hepatocellular Carcinoma (HCC)
Interventions: Drug: TAE plus P53 gene;   Other: TAE
17 Recruiting p53 and Response to Preoperative Radiotherapy for T2 and T3
Condition: Rectal Cancer
Intervention: Radiation: preoperative short course radiation
18 Recruiting Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes
Condition: Li-Fraumeni Syndrome
Intervention: Device: Whole Body MRI
19 Unknown  rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors
Condition: Advanced Oral and Maxillofacial Malignant Tumors
Interventions: Drug: p53 gene with surgery;   Procedure: surgery;   Drug: p53 with chemotherapy;   Drug: p53 gene therapy
20 Not yet recruiting p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Conditions: Ovarian Epithelial Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions: Drug: p53 gene;   Drug: Cisplatin;   Drug: Paclitaxel

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.